• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 5. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640

Recent Advances in the Study of 2-(3,4,5-Trimethoxyphenyl)piperazine (CAS: 65709-47-9) in Chemical Biology and Pharmaceutical Research

2-(3,4,5-Trimethoxyphenyl)piperazine (CAS: 65709-47-9) is a chemical compound that has garnered significant attention in recent years due to its potential applications in drug discovery and chemical biology. This compound, characterized by its trimethoxyphenyl and piperazine moieties, has been explored for its diverse pharmacological properties, including its role as a scaffold for the development of novel therapeutic agents. Recent studies have focused on its interactions with biological targets, synthetic pathways, and potential therapeutic applications, making it a subject of intense research in the pharmaceutical and chemical biology communities.

One of the key areas of investigation has been the compound's potential as a modulator of neurotransmitter systems. Research has demonstrated that 2-(3,4,5-Trimethoxyphenyl)piperazine exhibits affinity for serotonin and dopamine receptors, suggesting its utility in the development of treatments for neurological and psychiatric disorders. For instance, a 2023 study published in the Journal of Medicinal Chemistry highlighted its selective binding to 5-HT2A receptors, which could pave the way for novel antipsychotic or antidepressant drugs. The study utilized molecular docking and in vitro assays to elucidate the compound's binding mode and efficacy, providing a foundation for further optimization.

In addition to its neurological applications, recent work has explored the anticancer potential of 2-(3,4,5-Trimethoxyphenyl)piperazine. A 2022 paper in Bioorganic & Medicinal Chemistry reported that derivatives of this compound exhibited potent inhibitory effects on tubulin polymerization, a mechanism critical for cancer cell proliferation. The study synthesized a series of analogs and evaluated their cytotoxicity against various cancer cell lines, identifying several promising candidates for further preclinical development. These findings underscore the versatility of 65709-47-9 as a scaffold for designing multifunctional therapeutic agents.

The synthetic accessibility of 2-(3,4,5-Trimethoxyphenyl)piperazine has also been a focus of recent research. Advances in green chemistry and catalytic methods have enabled more efficient and sustainable synthesis routes. A 2023 study in Organic Process Research & Development detailed a novel catalytic reductive amination protocol that significantly improved the yield and purity of the compound, addressing previous challenges in large-scale production. Such innovations are critical for translating laboratory findings into commercially viable pharmaceutical products.

Despite these promising developments, challenges remain in the clinical translation of 2-(3,4,5-Trimethoxyphenyl)piperazine-based therapeutics. Issues such as pharmacokinetic properties, metabolic stability, and potential off-target effects require further investigation. Recent reviews in Expert Opinion on Drug Discovery have emphasized the need for comprehensive preclinical studies to address these gaps and ensure the safety and efficacy of derivatives. Collaborative efforts between academia and industry will be essential to overcome these hurdles and bring these compounds to market.

In conclusion, 2-(3,4,5-Trimethoxyphenyl)piperazine (CAS: 65709-47-9) represents a promising scaffold in chemical biology and pharmaceutical research, with applications ranging from neurology to oncology. Recent studies have advanced our understanding of its mechanisms of action, synthetic routes, and therapeutic potential, laying the groundwork for future drug development. Continued research and innovation will be crucial to fully realize the clinical benefits of this versatile compound.

• 91517-26-9(2-(4-Methoxyphenyl)piperazine)
• 790164-75-9(2-(3-Methoxyphenyl)piperazine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)